Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Prevalent Types of Peristomal Skin Damage During Chemoradiotherapy and Their Risk Factors
Publication Year: 2025 Source: Adv Wound Care (New Rochelle) PMID: 39912837
Significance: Colorectal cancer is currently ranked third in terms of the global cancer incidence. Enterostomy, a common surgical procedure for colorectal cancer treatment, creates a temporary or permanent stoma in the abdominal wall for waste excretion. Cancer itself and the associated treatments, such as chemotherapy and radiation therapy, increase the …
Winnie Mice: A Chronic and Progressive Model of Ulcerative Colitis
Publication Year: 2025 Source: Inflamm Bowel Dis PMID: 39912845 DOI: 10.1093/ibd/izaf006
Recent trends show a continuous worldwide rise in the incidence of ulcerative colitis (UC), leading to increased interest in its etiology and pathogenesis, which is currently unknown. To gain a better mechanistic understanding of this disease, many mouse models have been developed over the last several years, with variations of …
Association Between Genetically Proxied SLC12A2 Inhibition and Inflammatory Bowel Disease: A Mendelian Randomization Study
Publication Year: 2025 Source: Biochem Genet PMID: 39913044 DOI: 10.1007/s10528-025-11037-y
The global rise in hypertension prompts the use of medications to manage blood pressure. However, selecting first-line drugs remains challenging as their efficacy often stems from blood pressure reduction rather than specific pharmacological actions. Evaluating interactions between antihypertensive drugs and common diseases can aid tailored treatment. Here, we assess the …
A Longitudinal Post-authorization Safety Study of Golimumab in Treatment of Ulcerative Colitis: A Cohort Study in Denmark and Sweden, 2013-2021
Publication Year: 2025 Source: Drug Saf PMID: 39913070
BACKGROUND: When golimumab (GLM) was approved for the treatment of moderate to severe ulcerative colitis (UC) in 2013, a post-authorization safety study was conducted. OBJECTIVE: Our objective was to examine whether exposure to GLM was associated with an increased incidence of all-cause total colectomy, colorectal cancer, and hepatosplenic T-cell lymphoma …
Shengjiang Xiexin Decoction ameliorates DSS-induced ulcerative colitis via activating Wnt/β-Catenin signaling to enhance epithelium renovation and modulating intestinal flora
Publication Year: 2025 Source: Phytomedicine PMID: 39914063
BACKGROUND: Shengjiang Xiexin Decoction (SJXXD) is a recognized formulation in traditional Chinese medicine that is commonly employed in diarrhea treatment. It has the potential to be a viable alternative for treating ulcerative colitis (UC), but its therapeutic effects and mechanisms remain unclear. PURPOSE: This study aims to explore the effects …
Lymphatic messengers: Non-antigen soluble mediators from diseased tissues to draining lymph nodes
Publication Year: 2025 Source: Curr Opin Immunol PMID: 39914124
Tissues deliver not only antigens and cells via afferent lymphatics to draining lymph nodes during immune responses but also deliver soluble molecules that reflect the state of the tissue. In autoimmune diseases, these signals from affected tissues can potentially impact the magnitude or other characteristics of autoimmune responses generated in …
Applying the estimand framework to inflammatory bowel disease clinical trials
Publication Year: 2025 Source: Lancet Gastroenterol Hepatol PMID: 39914434
No Abstract
Gut Microbiome Signature in Predisease Phase of Inflammatory Bowel Disease: Prediction to Pathogenesis to Prevention
Publication Year: 2025 Source: Gastroenterology PMID: 39914464 DOI: 10.1053/j.gastro.2025.01.004
Advances in understanding the pathogenesis of inflammatory bowel disease (IBD) point toward a key role of the gut microbiome. We review the data describing the changes in the gut microbiome from IBD case-control studies and compare these findings with emerging data from studies of the preclinical phase of IBD. What …
Curcumin-loaded zein and shellac composite nanoparticles for ulcerative colitis treatment
Publication Year: 2025 Source: Eur J Pharm Biopharm PMID: 39914574
This study highlights the efficacy of microfluidic technology in creating curcumin (Cur) loaded zein + shellac (Z + S) hybrid nanoparticles (NPs), presenting a promising avenue for enhancing Cur's availability in the food industry, especially in beverages, and positioning it as a potent antioxidant strategy for applications such as the …
Body mass index does not influence loss of response to tumor necrosis factor inhibitors in Crohn's disease
Publication Year: 2025 Source: Gastroenterol Hepatol PMID: 39914694
OBJECTIVES: Moderate to severe Crohn's disease (CD) treatment was revolutionized by introducing anti-tumor necrosis factor (TNF) agents, which is still a cornerstone of the treatment. It is speculated that adipose tissue may influence treatment response, especially for non-weight-adjusted agents. PATIENTS AND METHODS: Research comparing the effectiveness of anti-TNFs between eutrophic …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide